[go: up one dir, main page]

Neurofibromatosis 1

"Neurofibromatosis 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).


expand / collapse Publications
This graph shows the total number of publications written about "Neurofibromatosis 1" by people in this website by year, and whether "Neurofibromatosis 1" was a major or minor topic of these publications.
Below are the most recent publications written about "Neurofibromatosis 1" by people in Profiles.
  1. Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. Clin Cancer Res. 2024 Dec 02; 30(23):5459-5472.
    View in: PubMed
  2. Eosinophilia in a Neonate With Trisomy 21, Transient Abnormal Myelopoiesis, and Neurofibromatosis Type 1. J Pediatr Hematol Oncol. 2024 Nov 01; 46(8):419-423.
    View in: PubMed
  3. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. Cell Rep Methods. 2024 May 20; 4(5):100772.
    View in: PubMed
  4. Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors. Curr Oncol Rep. 2024 Jun; 26(6):706-713.
    View in: PubMed
  5. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. Clin Cancer Res. 2024 03 01; 30(5):1038-1053.
    View in: PubMed
  6. Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. Nat Commun. 2024 Jan 12; 15(1):477.
    View in: PubMed
  7. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials. Clin Trials. 2024 02; 21(1):6-17.
    View in: PubMed
  8. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey. Clin Trials. 2024 02; 21(1):73-84.
    View in: PubMed
  9. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clin Trials. 2024 02; 21(1):51-66.
    View in: PubMed
  10. Melanocytic neoplasms in neurofibromatosis type 1: a systematic review. Melanoma Res. 2023 12 01; 33(6):437-446.
    View in: PubMed